Compare Fidelity National Information Servcs Inc (FIS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Sana Biotechnology Inc — how do they compare? Fidelity National Information Servcs Inc trades at $34.04 (market cap $17.71B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Fidelity National Information Servcs Inc is far larger — about 21.2× Sana Biotechnology Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and Sana Biotechnology Inc for 23 Days on average.
| FIS | SANA | |
|---|---|---|
Market Cap | $17.71B | $836.71M |
Volume | 9,047,825 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $67.94 | $5.92 |
52-Week Low | $32.44 | $2.68 |
Typical Hold Time | 88 Days | 23 Days |
Enterprise Value | $38.22B | $749.96M |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.34, up 1.54% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with revenue growth from $10.68B in 2025 to projected $12.2B in 2026 and net income margin expanding to 27.65%. Recent business wins include core banking platform selections and embedded banking launches, positioning FIS for modernization growth. Analyst consensus remains strongly bullish with a $47.15 price target representing 37% upside potential.
FIS presents a compelling value opportunity with attractive valuation multiples (P/E 5.27, P/S 1.46) and strong analyst support, though investors face risks from negative cash flow trends, high debt levels, and technical bearish signals. The company's strategic positioning in banking technology modernization provides growth catalysts, but execution risks and market volatility require careful monitoring.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative earnings, and substantial cash burn. The technical picture remains bearish with moving averages signaling continued downward pressure, though oscillators show neutral conditions. Recent earnings have been mixed with two misses and one beat against expectations, while analyst sentiment remains overwhelmingly positive with 82% buy ratings.
The outlook hinges on SANA's clinical pipeline success and future revenue generation capabilities. Investment opportunity exists in the company's promising biotechnology platform and strong analyst support, but risks include continued cash burn, lack of current revenue, and execution challenges in bringing therapies to market. The stock represents a high-risk, high-reward biotechnology investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
